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To the Editor:
Epidermal growth factor recep-
tor (EGFR) mutations are a well-estab-
lished predictor of response to EGFR 
tyrosine kinase inhibitors.1,2 Rare muta-
tions are present in a small percentage 
of cases, and in some cases, their pre-
dictive role is unknown. Here, we pres-
ent a complex infrequent mutation on 
exon 19 of EGFR in a patient treated 
with gefitinib.
CASE PRESENTATION
A white never smoker, 81-year-
old female was diagnosed in April 2013 
of a T4N2M1b lung adenocarcinoma 
(liver and lung metastases).
Mutational analysis was firstly 
performed using the TheraScreen 
EGFR mutation assay (Qiagen, 
Manchester, United Kingdom) in a 
real-time polymerase chain reaction 
(PCR) system (Rotor-GeneQ; Qiagen) 
following the manufacturer’s instruc-
tions. In addition, exons 18, 19, 20, and 
21 of the EGFR gene were amplified by 
conventional PCR followed by Sanger 
sequencing using BigDye 3.1 and 
analysis in a Genetic Analyzer 3500Dx 
(Applied Biosystems, Foster City, CA).
EGFR mutational analysis using 
the commercial kit TheraScreen did 
not detect any of the 29 mutations 
included in the assay. However, Sanger 
sequencing showed the presence of the 
p.L747_S752delinsQ mutation located 
at exon 19 of the EGFR gene (Fig. 1). 
This mutation results from a deletion of 
nucleotides 2239 to 2254 and insertion 
of four new nucleotides (CAAC). This 
infrequent and complex mutation is not 
included in the commercial kit. Thus, 
a negative result was obtained with the 
real-time PCR approach that is usually 
preferred in the clinical setting because 
of its increased sensitivity.
The patient began treatment with 
gefitinib 250 mg per daily with good tol-
erance and early clinical improvement. 
Response assessment by computerized 
tomography at 3 months demonstrated 
a partial response of lung and hepatic 
metastases (Fig. 2). However, because of 
neurological symptoms, she was subse-
quently diagnosed of brain and leptomen-
ingeal metastases. She received treatment 
with 30 Gy of whole-brain irradiation.
A switch to erlotinib was per-
formed because of evidence of improved 
control of leptomeningeal disease when 
compared with gefitinib.3 The patient 
remained clinically stable, without new 
neurological symptoms or seizure until 
the last follow-up at November 2013. She 
presented rapid deterioration of perfor-
mance status and died in December 2013.
DISCUSSION
Real-time PCR-based assays are 
preferred for EGFR mutational stud-
ies because of increased sensitivity. 
However, in cases with clinical char-
acteristics enriched in patients with 
EGFR mutations (nonsmoker, females), 
Sanger sequencing can identify rare 
mutations, which cannot be detected by 
some commercial assays, if the mutant 
allele burden is above 15%. In this case, 
we describe this uncommon deletion/
insertion detected by Sanger sequenc-
ing that derived in initial clinical benefit 
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FIGURE 1.  Sequencing chromatogram showing the mutation affecting exon 19 
(p.L747_S752delinsQ) of the EGFR gene (NM_55228.3). EGFR, epidermal growth 
factor receptor.
FIGURE 2.  Lung CT scan illustrating the partial response to gefitinib (left: before 
starting treatment, right: after 3 months on gefitinib 250 mg/day). CT, computed 
tomography.
LETTER TO THE EDITOR
e48 Copyright © 2014 by the International Association for the Study of Lung Cancer
Letters to the Editor Journal of Thoracic Oncology ®  •  Volume 9, Number 6, June 2014
from EGFR tyrosine kinase inhibitors 
for this patient. However, central ner-
vous system and leptomeningeal pro-
gression appearance during treatment 
may have accounted for the relatively 
short survival of this patient (8 months). 
It could also be hypothesized that sensi-
tivity conferred by this rare mutation is 
not long lasting.
It remains of high importance to 
describe the behavior of these uncom-
mon mutations to guide a clinician fac-
ing these challenging cases in everyday 
practice.
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